Video
Dr. DiBiase on Data With DM-CHOC-PEN/Radiation in Cancers Involving the CNS
Author(s):
Steven J. DiBiase, MD, chair and chief of service for the Julia and Ned Arnold Center for Radiation Oncology, NewYork-Presbyterian Queens, vice chairman and assistant interim professor of radiation oncology, Weill Cornell Medicine, discusses data with 4-demethyl-4 cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) plus radiation in cancers involving the central nervous system (CNS).
Steven J. DiBiase, MD, chair and chief of service for the Julia and Ned Arnold Center for Radiation Oncology, NewYork-Presbyterian Queens, vice chairman and assistant interim professor of radiation oncology, Weill Cornell Medicine, discusses data with 4-demethyl-4 cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) plus radiation in cancers involving the central nervous system (CNS).
As part of the virtual platform for the 2020 AACR Annual Meeting, DiBiase presented the results from a phase 1 study evaluating DM-CHOC-PEN plus radiation in cancers involving the CNS. In the trial, patients received DM-CHOC-PEN at doses ranging from 39 mg/m2 to 98.7 mg/m2. Patients with liver disease were dose reduced to 75 mg/m2.
The recommended phase 2 dose of DM-CHOC-PEN in combination with radiation was determined to be 98.7 mg/m2. To date, investigators have treated 19 patients with the combined modality approach. The drug was found to be well tolerated, says DiBiase. In terms of adverse events, investigators reported 1 case of grade 2 seizure and 1 case of grade 2 vasogenic edema, both of which resolved with medical therapy.
